Patents by Inventor Daniel H. Bedinger

Daniel H. Bedinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies that bind interleukin-2 and uses thereof
    Patent number: 12234285
    Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: February 25, 2025
    Assignees: XOMA (US) LLC, MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
  • Antibodies that bind transforming growth factor beta (TGF beta) and methods of use thereof for treatment
    Patent number: 12071475
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: August 27, 2024
    Assignee: XOMA TECHNOLOGY LTD.
    Inventors: Daniel H. Bedinger, Shireen S. Khan, Amer M. Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • PARATHYROID HORMONE RECEPTOR 1(PTH1R) ANTIBODIES AND USES THEREOF
    Publication number: 20240158535
    Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
    Type: Application
    Filed: September 7, 2023
    Publication date: May 16, 2024
    Inventors: Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
  • Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
    Patent number: 11787876
    Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: October 17, 2023
    Assignee: XOMA (US) LLC
    Inventors: Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
  • Antibodies Specific for TGF-Beta
    Publication number: 20210355204
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Application
    Filed: July 15, 2021
    Publication date: November 18, 2021
    Inventors: Daniel H. Bedinger, Shireen S. Khan, Amer M. Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • ANTIBODIES THAT BIND INTERLEUKIN-2 AND USES THEREOF
    Publication number: 20210188969
    Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 24, 2021
    Inventors: Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
  • Antibodies that bind interleukin-2 and uses thereof
    Patent number: 10858428
    Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 8, 2020
    Assignees: XOMA (US) LLC, MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
  • Parathyroid Hormone Receptor 1 (PTH1R) Antibodies and Uses Thereof
    Publication number: 20200317817
    Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
    Type: Application
    Filed: November 26, 2019
    Publication date: October 8, 2020
    Inventors: Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshikiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
  • Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
    Patent number: 10519250
    Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: December 31, 2019
    Assignee: XOMA (US) LLC
    Inventors: Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
  • Antibodies Specific for TGF-Beta
    Publication number: 20190315850
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 17, 2019
    Inventors: Daniel H. Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Antibodies That Bind Interleukin-2 and Uses Thereof
    Publication number: 20180094053
    Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
    Type: Application
    Filed: September 28, 2017
    Publication date: April 5, 2018
    Inventors: Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
  • Parathyroid Hormone Receptor 1 (PTH1R) Antibodies and Uses Thereof
    Publication number: 20180030154
    Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
    Type: Application
    Filed: August 1, 2017
    Publication date: February 1, 2018
    Inventors: Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter